Sonnet BioTherapeutics Holdings, Inc.
SONNDelisted Dec 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001106838
Sonnet BioTherapeutics Holdings, Inc. was delisted on Dec 2, 2025; its insiders filed their last Form 4 on Dec 4, 2025; 27 institutions reported holding it in 13F filings for Q3 2025, worth $3.53M in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in Sonnet BioTherapeutics Holdings, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 8
- −1 vs. Q4 2024
- Shares held
- 161.3K
- +72.2K (+81.1%) vs. Q4 2024
- Total value
- $216.1K
- +$85.9K (+66.0%) vs. Q4 2024
- New holders
- 3
- 2 more added
- Sold out
- 4
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SONN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $170.3K |
| Q3 2025 | 27 | $3.53M |
| Q2 2025 | 9 | $223.7K |
| Q1 2025 | 8 | $216.1K |
| Q4 2024 | 9 | $130.2K |
| Q3 2024 | 3 | $2.97K |
| Q2 2024 | 11 | $550.0K |
| Q1 2024 | 10 | $117.6K |
| Q4 2023 | 10 | $157.8K |
| Q3 2023 | 10 | $110.1K |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Sonnet BioTherapeutics Holdings, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MMCAP International Inc. SPC | 133,590 | $179.0K | 0.03% | +133,590 | New |
| Geode Capital Management, LLC | 24,805 | $33.2K | 0.00% | +24,805 | New |
| Tower Research Capital LLC (TRC) | 2,587 | $3.47K | 0.00% | −3,513−57.6% | Reduced |
| UBS Group AG | 141 | $189 | 0.00% | +138+4,600.0% | Added |
| BlackRock, Inc. | 65 | $87 | 0.00% | 00.0% | Unchanged |
| Carolina Wealth Advisors, LLC | 32 | $43 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 26 | $35 | 0.00% | +21+420.0% | Added |
| Barclays PLC | 17 | $23 | 0.00% | +17 | New |
| Virtu Financial LLC | 0 | $0 | 0.00% | −39,647−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −24,013−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −19,203−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −2−100.0% | Sold out |